BusinessCempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 StudyBy Nasdaq OMXSep 29, 2016, 8:15 PM UTC
BusinessCempra to Present at Three Upcoming Investor ConferencesBy Nasdaq OMXSep 1, 2016, 11:30 AM UTC
BusinessCempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious DiseasesBy Nasdaq OMXAug 25, 2016, 8:05 PM UTC
BusinessCempra to Present at the Needham and Company 15th Annual Healthcare ConferenceBy Nasdaq OMXApr 6, 2016, 11:30 AM UTC
BusinessCempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9By Nasdaq OMXMar 8, 2016, 9:10 PM UTC
BusinessCempra to Present at the Cowen and Company 36th Annual Healthcare ConferenceBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessCempra to Report Fourth Quarter and Full Year 2015 Financial ResultsBy Nasdaq OMXFeb 17, 2016, 12:30 PM UTC
